[1,2,4]Triazolo[4,3-a]phthalazines: Inhibitors of diverse bromodomains

Journal of Medicinal Chemistry

Volumn 57, Issue 2, 2014, Pages 462-476

  Fedorov, Oleg ^a   Lingard, Hannah ^a   Wells, Chris ^a   Monteiro, Octovia P ^a   Picaud, Sarah ^a   Keates, Tracy ^a   Yapp, Clarence ^a   Philpott, Martin ^a   Martin, Sarah J ^a   Felletar, Ildiko ^a   Marsden, Brian D ^a,b   Filippakopoulos, Panagis ^a   Müller, Susanne ^a   Knapp, Stefan ^a   Brennan, Paul E ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [3 (3 METHYL [1,2,4]TRIAZOLO[3,4 A]PHTHALAZIN 6 YL)PHENYL]ACETIC ACID; 2 CHLORO N [5 (3 METHYL [1,2,4]TRIAZOLO[3,4 A]PHTHALAZIN 6 YL) 2 MORPHOLINOPHENYL] BENZENESULFONAMIDE; 3 (3 METHYL [1,2,4]TRIAZOLO[3,4 A]PHTHALAZIN 6 YL) 5 NITROBENZOIC ACID; 3 (3 METHYL [1,2,4]TRIAZOLO[3,4 A]PHTHALAZIN 6 YL)BENZOIC ACID; 3 [3 (AMINOMETHYL) [1,2,4]TRIAZOLO[3,4 A]PHTHALAZIN 6 YL] N BENZYLBENZENESULFONAMIDE; 3 CHLORO N [5 (3 METHYL [1,2,4]TRIAZOLO[3,4 A]PHTHALAZIN 6 YL) 2 MORPHOLINOPHENYL] BENZENESULFONAMIDE; 3 METHYL 6 PHENYL [1,2,4]TRIAZOLO[3,4 A]PHTHALAZINE; 3,5 DICHLORO N [5 (3 METHYL [1,2,4]TRIAZOLO[3,4 A]PHTHALAZIN 6YL) 2 MORPHOLINOPHENYL] BENZENESULFONAMIDE; 4 [4 (3 METHYL [1,2,4]TRIAZOLO[3,4 A]PHTHALAZIN 6 YL) 2 NITROPHENYL]MORPHOLINE; 4 CHLORO 3 (3 METHYL [1,2,4]TRIAZOLO[3,4 A]PHTHALAZIN 6 YL)ANILINE; 4 CHLORO N [5 (3 METHYL [1,2,4]TRIAZOLO[3,4 A]PHTHALAZIN 6 YL) 2 MORPHOLINOPHENYL] BENZENESULFONAMIDE; 4 CHLORO N {5 [3 (HYDROXYMETHYL) [1,2,4]TRIAZOLO[3,4 A]PHTHALAZIN 6 YL] 2 MORPHOLINO PHENYL}BENZENESULFONAMIDE; 4 METHOXY N [5 (3 METHYL [1,2,4]TRIAZOLO[3,4 A]PHTHALAZIN 6 YL) 2 (4 METHYLPIPERAZIN 1 YL)PHENYL]BENZENESULFONAMIDE; 4 METHYL N [5 (3 METHYL [1,2,4]TRIAZOLO[3,4 A]PHTHALAZIN 6 YL) 2 MORPHOLINOPHENYL] BENZENESULFONAMIDE; 5 (3 METHYL [1,2,4]TRIAZOLO[3,4 A]PHTHALAZIN 6 YL) 2 MORPHOLINOANILINE; 6 (2 CHLORO 5 NITROPHENYL) 3 METHYL [1,2,4]TRIAZOLO[3,4 A]PHTHALAZINE; 6 CHLORO 3 METHYL [1,2,4]TRIAZOLO[3,4 A]PHTHALAZINE; [1,2,4]TRIAZOLO[4,3 A ]PHTHALAZINE; N [3 CHLORO 5 (3 METHYL [1,2,4]TRIAZOLO[3,4 A]PHTHALAZIN 6 YL) PHENYL]BENZENESULFONAMIDE; N [4 CHLORO 3 (3 METHYL [1,2,4]TRIAZOLO[3,4 A]PHTHALAZIN 6 YL) PHENYL]BENZENESULFONAMIDE; N [5 (3 METHYL [1,2,4]TRIAZOLO[3,4 A]PHTHALAZIN 6 YL) 2 MORPHOLINOPHENYL]METHANE SULFONAMIDE; N BENZYL 3 (3 CYCLOPROPYL [1,2,4]TRIAZOLO[3,4 A]PHTHALAZIN 6 YL)BENZENESULFONAMIDE; N BENZYL 3 (3 ETHYL [1,2,4]TRIAZOLO[3,4 A]PHTHALAZIN 6 YL)BENZENESULFONAMIDE; N BENZYL 3 (3 METHYL [1,2,4]TRIAZOLO[3,4 A]PHTHALAZIN 6 YL)BENZENESULFONAMIDE; N BENZYL 3 [3 (HYDROXYMETHYL) [1,2,4]TRIAZOLO[3,4 A]PHTHALAZIN 6 YL]BENZENESULFONAMIDE; N {5 [3 (AMINOMETHYL) [1,2,4]TRIAZOLO[3,4 A]PHTHALAZIN 6 YL] 2 MORPHOLINOPHENYL} 4 CHLOROBENZENESULFONAMIDE; PHTHALAZINE DERIVATIVE; TERT BUTYL [[6 [3 (N BENZYLSULFAMOYL)PHENYL] [1,2,4]TRIAZOLO[3,4 A]PHTHALAZIN 3 YL] METHYL]CARBAMATE; UNCLASSIFIED DRUG;

ARTICLE; CHROMATIN; CRYSTALLIZATION; DRUG SYNTHESIS; FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING; HYDROGEN BOND; LIGAND BINDING; PHYLOGENETIC TREE; SEQUENCE ALIGNMENT; SUZUKI REACTION; X RAY CRYSTALLOGRAPHY;

CELL LINE, TUMOR; CHROMATIN ASSEMBLY AND DISASSEMBLY; CREB-BINDING PROTEIN; CRYSTALLOGRAPHY, X-RAY; HUMANS; MOLECULAR DOCKING SIMULATION; NUCLEAR PROTEINS; PHTHALAZINES; PROTEIN STRUCTURE, TERTIARY; PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION FACTORS; TRIAZOLES;

EID: 84893130847     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401568s     Document Type: Article

References (43)

1. Zentner, G. E.; Henikoff, S. Regulation of nucleosome dynamics by histone modifications Nature Struct. Mol. Biol. 2013, 20 (3) 259-266
2. Dawson, M. A.; Kouzarides, T. Cancer Epigenetics: From Mechanism to Therapy Cell 2012, 150 (1) 12-27
3. Brennan, P.; Filippakopoulos, P.; Knapp, S. The therapeutic potential of acetyl-lysine and methyl-lysine effector domains Drug Discovery Today: Ther. Strategies 2012, 9 (2-3) e101-e110
4. Muller, S.; Filippakopoulos, P.; Knapp, S. Bromodomains as therapeutic targets Expert Rev. Mol. Med. 2011, 13, e29/1-e29/21
5. Hewings, D. S.; Rooney, T. P. C.; Jennings, L. E.; Hay, D. A.; Schofield, C. J.; Brennan, P. E.; Knapp, S.; Conway, S. J. Progress in the Development and Application of Small Molecule Inhibitors of Bromodomain-Acetyl-lysine Interactions J. Med. Chem. 2012, 55 (22) 9393-9413
6. Müller, S.; Lingard, H.; Knapp, S., Selective Inhibition of Acetyl-Lysine Effector Domains of the Bromodomain Family in Oncology. In Nuclear Signaling Pathways and Targeting Transcription in Cancer; Kumar, R., Ed.; Springer: New York: 2014; pp 279-298.
7. Filippakopoulos, P.; Qi, J.; Picaud, S.; Shen, Y.; Smith, W. B.; Fedorov, O.; Morse, E. M.; Keates, T.; Hickman, T. T.; Felletar, I.; Philpott, M.; Munro, S.; McKeown, M. R.; Wang, Y.; Christie, A. L.; West, N.; Cameron, M. J.; Schwartz, B.; Heightman, T. D.; La Thangue, N.; French, C. A.; Wiest, O.; Kung, A. L.; Knapp, S.; Bradner, J. E. Selective inhibition of BET bromodomains Nature 2010, 468 (7327) 1067-1073
8. Hewings, D. S.; Wang, M.; Philpott, M.; Fedorov, O.; Uttarkar, S.; Filippakopoulos, P.; Picaud, S.; Vuppusetty, C.; Marsden, B.; Knapp, S.; Conway, S. J.; Heightman, T. D. 3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands J. Med. Chem. 2011, 54 (19) 6761-6770
9. Dawson, M. A.; Prinjha, R. K.; Dittmann, A.; Giotopoulos, G.; Bantscheff, M.; Chan, W.-I.; Robson, S. C.; Chung, C.-w.; Hopf, C.; Savitski, M. M.; Huthmacher, C.; Gudgin, E.; Lugo, D.; Beinke, S.; Chapman, T. D.; Roberts, E. J.; Soden, P. E.; Auger, K. R.; Mirguet, O.; Doehner, K.; Delwel, R.; Burnett, A. K.; Jeffrey, P.; Drewes, G.; Lee, K.; Huntly, B. J. P.; Kouzarides, T. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia Nature 2011, 478 (7370) 529-533
10. Bamborough, P.; Diallo, H.; Goodacre, J. D.; Gordon, L.; Lewis, A.; Seal, J. T.; Wilson, D. M.; Woodrow, M. D.; Chung, C.-w. Fragment-Based Discovery of Bromodomain Inhibitors Part 2: Optimization of Phenylisoxazole Sulfonamides J. Med. Chem. 2011, 55 (2) 587-596
11. Hay, D.; Fedorov, O.; Filippakopoulos, P.; Martin, S.; Philpott, M.; Picaud, S.; Hewings, D. S.; Uttakar, S.; Heightman, T. D.; Conway, S. J.; Knapp, S.; Brennan, P. E. The design and synthesis of 5- and 6- isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains MedChemComm 2013, 4 (1) 140-144
12. Hewings, D. S.; Fedorov, O.; Filippakopoulos, P.; Martin, S.; Picaud, S.; Tumber, A.; Wells, C.; Olcina, M. M.; Freeman, K.; Gill, A.; Ritchie, A. J.; Sheppard, D. W.; Russell, A. J.; Hammond, E. M.; Knapp, S.; Brennan, P. E.; Conway, S. J. Optimization of 3,5-Dimethylisoxazole Derivatives as Potent Bromodomain Ligands J. Med. Chem. 2013, 56 (8) 3217-3227
13. Albrecht, B. K.; Audia, J. E.; Cote, A.; Gehling, V. S.; Harmange, J.-C.; Hewitt, M. C.; Leblanc, Y.; Naveschuk, C. G.; Taylor, A. M.; Vaswani, R. G. Preparation of compounds containing azepine-based ring systems as bromodomain-containing protein inhibitors and therapeutic uses thereof. WO2012075383A2, 2012.
14. Picaud, S.; Da Costa, D.; Thanasopoulou, A.; Filippakopoulos, P.; Fish, P. V.; Philpott, M.; Fedorov, O.; Brennan, P.; Bunnage, M. E.; Owen, D. R.; Bradner, J. E.; Taniere, P.; O'Sullivan, B.; Müller, S.; Schwaller, J.; Stankovic, T.; Knapp, S. PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains Cancer Res. 2013, 73 (11) 3336-3346
15. Nicodeme, E.; Jeffrey, K. L.; Schaefer, U.; Beinke, S.; Dewell, S.; Chung, C.-w.; Chandwani, R.; Marazzi, I.; Wilson, P.; Coste, H.; White, J.; Kirilovsky, J.; Rice, C. M.; Lora, J. M.; Prinjha, R. K.; Lee, K.; Tarakhovsky, A. Suppression of inflammation by a synthetic histone mimic Nature 2010, 468 (7327) 1119-1123
16. Mirguet, O.; Lamotte, Y.; Donche, F.; Toum, J.; Gellibert, F.; Bouillot, A.; Gosmini, R.; Nguyen, V.-L.; Delannée, D.; Seal, J.; Blandel, F.; Boullay, A.-B.; Boursier, E.; Martin, S.; Brusq, J.-M.; Krysa, G.; Riou, A.; Tellier, R.; Costaz, A.; Huet, P.; Dudit, Y.; Trottet, L.; Kirilovsky, J.; Nicodeme, E. From ApoA1 upregulation to BET family bromodomain inhibition: Discovery of I-BET151 Bioorg. Med. Chem. Lett. 2012, 22 (8) 2963-2967
17. Zuber, J.; Shi, J.; Wang, E.; Rappaport, A. R.; Herrmann, H.; Sison, E. A.; Magoon, D.; Qi, J.; Blatt, K.; Wunderlich, M.; Taylor, M. J.; Johns, C.; Chicas, A.; Mulloy, J. C.; Kogan, S. C.; Brown, P.; Valent, P.; Bradner, J. E.; Lowe, S. W.; Vakoc, C. R. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia Nature 2011, 478 (7370) 524-528
18. Wu, S.-Y.; Lee, A. Y.; Lai, H.-T.; Zhang, H.; Chiang, C.-M. Phospho Switch Triggers Brd4 Chromatin Binding and Activator Recruitment for Gene-Specific Targeting Mol. Cell 2013, 49 (5) 843-857
19. Banerjee, C.; Archin, N.; Michaels, D.; Belkina, A. C.; Denis, G. V.; Bradner, J.; Sebastiani, P.; Margolis, D. M.; Montano, M. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1 J. Leukocyte Biol. 2012, 92 (6) 1147-1154
20. Li, Z.; Guo, J.; Wu, Y.; Zhou, Q. The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation Nucleic Acids Res. 2013, 41 (1) 277-287
21. Chung, C.-W.; Nicodeme, E. Quinoline, azoloquinoline, triazolobenzodiazepine derivatives as bromodomain inhibitors for treating autoimmune and inflammatory diseases and their preparation. WO2011054843A1, 2011.
22. Albrecht, B. K.; Harmange, J.-C.; Cote, A.; Taylor, A. M. Bromodomain inhibitors for cancer therapy. WO2012174487A2, 2012.
23. Filippakopoulos, P.; Picaud, S.; Mangos, M.; Keates, T.; Lambert, J.-P.; Barsyte-Lovejoy, D.; Felletar, I.; Volkmer, R.; Müller, S.; Pawson, T.; Gingras, A.-C.; Arrowsmith; Cheryl, H.; Knapp, S. Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family Cell 2012, 149 (1) 214-231
24. Compounds 5-12 and 14-17 were purchased from Interbioscreen (http://www.ibscreen.com).
25. Chung, C.-w.; Dean, T. W.; Woolven, J. M.; Bamborough, P. Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery J. Med. Chem. 2011, 55 (2) 576-586
26. Totrov, M.; Abagyan, R. Flexible protein-ligand docking by global energy optimization in internal coordinates Proteins 1997, Suppl 1, 215-220 (Pubitemid 28090502)
27. Philpott, M.; Yang, J.; Tumber, T.; Fedorov, O.; Uttarkar, S.; Filippakopoulos, P.; Picaud, S.; Keates, T.; Felletar, I.; Ciulli, A.; Knapp, S.; Heightman, T. D. Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery Mol. BioSyst. 2011, 7 (10) 2899-2908
28. Calculated using the free ACD/I-Lab calculator at http://ilab.cds.rsc. org.
29. Mullighan, C. G.; Zhang, J.; Kasper, L. H.; Lerach, S.; Payne-Turner, D.; Phillips, L. A.; Heatley, S. L.; Holmfeldt, L.; Collins-Underwood, J. R.; Ma, J.; Buetow, K. H.; Pui, C.-H.; Baker, S. D.; Brindle, P. K.; Downing, J. R. CREBBP mutations in relapsed acute lymphoblastic leukaemia Nature 2011, 471 (7337) 235-239
30. Vidler, L. R.; Brown, N.; Knapp, S.; Hoelder, S. Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding Sites J. Med. Chem. 2012, 55 (17) 7346-7359
31. Edwards, A. M.; Bountra, C.; Kerr, D. J.; Willson, T. M. Open access chemical and clinical probes to support drug discovery Nature Chem. Biol. 2009, 5 (7) 436-440
32. Sternfeld, F.; Carling, R. W.; Jelley, R. A.; Ladduwahetty, T.; Merchant, K. J.; Moore, K. W.; Reeve, A. J.; Street, L. J.; O'Connor, D.; Sohal, B.; Atack, J. R.; Cook, S.; Seabrook, G.; Wafford, K.; Tattersall, F. D.; Collinson, N.; Dawson, G. R.; Castro, J. L.; MacLeod, A. M. Selective, Orally Active γ-Aminobutyric AcidA α5 Receptor Inverse Agonists as Cognition Enhancers J. Med. Chem. 2004, 47 (9) 2176-2179 (Pubitemid 38478841)
33. Garino, C.; Tomita, T.; Pietrancosta, N.; Laras, Y.; Rosas, R.; Herbette, G.; Maigret, B.; Quéléver, G.; Iwatsubo, T.; Kraus, J.-L. Naphthyl and Coumarinyl Biarylpiperazine Derivatives as Highly Potent Human β-Secretase Inhibitors. Design, Synthesis, and Enzymatic BACE-1 and Cell Assays J. Med. Chem. 2006, 49 (14) 4275-4285 (Pubitemid 44036671)
34. French, C. A.; Ramirez, C. L.; Kolmakova, J.; Hickman, T. T.; Cameron, M. J.; Thyne, M. E.; Kutok, J. L.; Toretsky, J. A.; Tadavarthy, A. K.; Kees, U. R.; Fletcher, J. A.; Aster, J. C. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells Oncogene 2007, 27 (15) 2237-2242 (Pubitemid 351483375)
35. Kedersha, N.; Tisdale, S.; Hickman, T.; Anderson, P. Real-time and quantitative imaging of mammalian stress granules and processing bodies Methods Enzymol. 2008, 448, 521-552
36. Phair, R. D.; Gorski, S. A.; Misteli, T. Measurement of dynamic protein binding to chromatin in vivo, using photobleaching microscopy Methods Enzymol. 2004, 375, 393-414 (Pubitemid 38124881)
37. Leslie, A. G. W.; Powell, H. MOSFLM, 7.01; MRC Laboratory of Molecular Biology: Cambridge, 2007.
38. Evans, P. SCALA-scale Together Multiple Observations of Reflections, 3.3.0; MRC Laboratory of Molecular Biology: Cambridge, 2007.
39. McCoy, A. J.; Grosse-Kunstleve, R. W.; Storoni, L. C.; Read, R. J. Likelihood-enhanced fast translation functions Acta Crystallogr., Sect. D: Biol. Crystallogr. 2005, 61, 458-464 (Pubitemid 43934606)
40. Perrakis, A.; Morris, R.; Lamzin, V. S. Automated protein model building combined with iterative structure refinement Nature Struct. Biol. 1999, 6 (5) 458-463 (Pubitemid 29218016)
41. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126-2132 (Pubitemid 41742764)
42. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53, 240-255 (Pubitemid 27235885)
43. Painter, J.; Merritt, E. A. Optimal description of a protein structure in terms of multiple groups undergoing TLS motion Acta Crystallogr., Sect. D: Biol. Crystallogr. 2006, 62, 439-450